tiprankstipranks

Regeneron Shareholders Approve Key Proposals at 2025 Meeting

Story Highlights
  • Regeneron shareholders confirmed the election of directors and approved the accounting firm for 2025.
  • Proposals to declassify the board passed, but eliminating supermajority vote requirements failed.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Regeneron Shareholders Approve Key Proposals at 2025 Meeting

Don’t Miss TipRanks’ Half-Year Sale

Regeneron ( (REGN) ) has provided an update.

At the 2025 Annual Meeting of Shareholders held on June 13, Regeneron Pharmaceuticals’ shareholders voted on several key proposals. The election of Class I directors was confirmed, with nominees set to serve until the 2028 meeting. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. Additionally, an advisory vote approved the executive compensation package. A significant amendment to declassify the board of directors was passed, while proposals to eliminate supermajority vote requirements for certain amendments to the company’s Certificate of Incorporation were not approved.

The most recent analyst rating on (REGN) stock is a Hold with a $940.00 price target. To see the full list of analyst forecasts on Regeneron stock, see the REGN Stock Forecast page.

Spark’s Take on REGN Stock

According to Spark, TipRanks’ AI Analyst, REGN is a Neutral.

Regeneron’s overall stock score reflects strong financial performance and a reasonable valuation. However, bearish technical indicators and mixed earnings call results highlight challenges and uncertainties, balancing the positive financial aspects.

To see Spark’s full report on REGN stock, click here.

More about Regeneron

Regeneron Pharmaceuticals, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of medicines for serious diseases. The company operates in the pharmaceutical industry and is known for its innovative approach to drug development, targeting areas such as ophthalmology, oncology, and immunology.

Average Trading Volume: 1,334,973

Technical Sentiment Signal: Sell

Current Market Cap: $56.43B

Find detailed analytics on REGN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1